FluGen, Inc
- Biotech or pharma, therapeutic R&D
FluGen is working to establish more effective vaccines. Our lead live, intranasal influenza vaccine, M2SR, has been studied in over 700 subjects from 6 mos to 85 years. M2SR is also being developed as a vector to deliver other viral antigens.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}